MAR 24, 2020 5:51 AM PDT

Ultra sensitive cancer diagnostic detects DNA "fingerprints" in liquid biopsies

WRITTEN BY: Tara Fernandez

Researchers from the Broad and Dana-Farber Cancer Institutes have developed a diagnostic technology that can be used to monitor patients for the presence of recurring cancer cells after receiving treatment. This “liquid biopsy” screening platform is so sensitive, that it can detect metastatic cancer cells years before they would show up using traditional techniques.

The retrospective study, published in Clinical Cancer Research, tracked banked blood samples from breast cancer patients in the years following their initial diagnosis and treatment. Nearly 30 percent of women diagnosed with breast cancer will develop metastatic disease, as a result of cancer cells breaking away from the original tumor in the breast and migrating to other parts of the body through the bloodstream or the lymphatic system.

Senior author Viktor Adalsteinsson and his team first used whole-exome DNA sequencing to identify the unique DNA “fingerprint” from the tumors isolated from each of the 142 patients in the study. Significantly, the researchers found trace amounts of these cancer DNA sequences in the patients’ blood samples up to three years before metastatic cancer recurrence was picked up using standard diagnostic approaches.

“By taking an individualized approach — searching for many mutations that are specific to one patient’s cancer — we could greatly increase our sensitivity to detect traces of cancer DNA in patients who had completed their initial treatment plan,” explained Adalsteinsson.

“And with that sensitivity, we could identify residual cancer from blood samples taken many months to years before a recurring case was diagnosed through standard approaches.”

Future studies are going to employ whole-genome sequencing to boost the test’s sensitivity by collecting more genetic information about the patient’s tumor. In whole-genome sequencing, large amounts of DNA are sequenced at a single time, allowing researchers to perform a more in-depth characterization of the patient’s entire genome. 

With this technology, cancer patients would be able to receive more timely interventions should their cancer return or residual malignant cells be present after their initial treatment.

According to Adalsteinsson, “When we did detect residual disease in blood, following initial courses of treatment, it was a strong predictor of future recurrence. While this was a retrospective study, if a blood biopsy can give clinicians this early warning in real-time, that might provide the opportunity to alter a patient’s outcome.”

 

 


Source: The Harvard Gazette, Clinical Cancer Research.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 10, 2020
Cancer
Researching New RNA Biomarkers for Liver Cancer
JUL 10, 2020
Researching New RNA Biomarkers for Liver Cancer
The most important part of cancer treatment is the first step, diagnosis. Many cancers can lie dormant for years, reachi ...
AUG 04, 2020
Clinical & Molecular DX
Alzheimer's Blood Test Serves as a Crystal Ball
AUG 04, 2020
Alzheimer's Blood Test Serves as a Crystal Ball
According to a recent study, the answers could lie in a simple blood test.
SEP 07, 2020
Cancer
Identifying Robust Tumor Features for Better Radiomics
SEP 07, 2020
Identifying Robust Tumor Features for Better Radiomics
With the advancement of technology comes the renovation of classical medical techniques. Diagnostic is one of the areas ...
SEP 17, 2020
Clinical & Molecular DX
Blood Vessels on a Chip Test Clotting
SEP 17, 2020
Blood Vessels on a Chip Test Clotting
Blood clotting, also known as coagulation, is a critical biological mechanism to prevent excessive blood loss in the eve ...
SEP 21, 2020
Cancer
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
SEP 21, 2020
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
Cancer is an incredibly diverse disease. It has many types and even sub-types, with a vast range of characteristics. Som ...
OCT 24, 2020
Clinical & Molecular DX
Software Flags Elevated Cerebral Palsy Risk in Premies
OCT 24, 2020
Software Flags Elevated Cerebral Palsy Risk in Premies
Diagnostic imaging scientists have developed a software tool for predicting the future onset of cerebral palsy in babies ...
Loading Comments...